RET Alterations Differentiate Molecular Profile of Medullary Thyroid Cancer
Kumar Prabhash,Elveera Saldanha,Vijay Patil,Munita Bal,Sreekanth Reddy P,Airy Sanjeev,Raunak Kumar,Disha Poojary,Vanita Noronha,Nandini Menon,Neha Mittal,Vaishakhi Trivedi,Kavya Nambiar,Rohit Mishra,Nishtha Tanwar,Richa Malhotra,Priyanka Pange,Vinod Gupta,Vidya H Veldore,Anuradha Chougule,Pankaj Chaturvedi,Amit Dutt,Pratik Chandrani
DOI: https://doi.org/10.1200/PO.23.00622
Abstract:Purpose: Medullary thyroid cancer (MTC) is a rare cancer originating from parafollicular C cells of the thyroid gland. Therapeutically relevant alterations in MTC are predominantly reported in RET oncogene, and lower-frequency alterations are reported in KRAS and BRAF. Nevertheless, there is an unmet need existing to analyze the MTC in the Indian cohort by using in-depth sequencing techniques that go beyond the identification of known therapeutic biomarkers. Materials and methods: Here, we characterize MTC using integrative whole-exome and whole-transcriptome sequencing of 32 MTC tissue samples. We performed clinically relevant variant analysis, molecular pathway analysis, tumor immune-microenvironment analysis, and structural characterization of RET novel mutation. Results: Mutational landscape analysis shows expected RET mutations in 50% of the cases. Furthermore, we observed mutations in known cancer genes like KRAS, HRAS, SF3B1, and BRAF to be altered only in the RET-negative cohort. Pathway analysis showed differential enrichment of mutations in transcriptional deregulation genes in the RET-negative cohort. Furthermore, we observed novel RET kinase domain mutation Y900S showing affinity to RET inhibitors accessed via molecular docking and molecular dynamics simulation. Conclusion: Altogether, this study provides a detailed genomic characterization of patients with MTC of Indian origin, highlighting the possible utility of targeted therapies in this disease.